WO2005115442A1 - Utilisation du facteur xiii de coagulation dans le traitement de saignements post-operatoires - Google Patents

Utilisation du facteur xiii de coagulation dans le traitement de saignements post-operatoires Download PDF

Info

Publication number
WO2005115442A1
WO2005115442A1 PCT/EP2005/052324 EP2005052324W WO2005115442A1 WO 2005115442 A1 WO2005115442 A1 WO 2005115442A1 EP 2005052324 W EP2005052324 W EP 2005052324W WO 2005115442 A1 WO2005115442 A1 WO 2005115442A1
Authority
WO
WIPO (PCT)
Prior art keywords
factor
factor xiii
surgery
patient
xiii
Prior art date
Application number
PCT/EP2005/052324
Other languages
English (en)
Inventor
Marianne Kjalke
Rasmus RØJKJÆR
Original Assignee
Novo Nordisk Health Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Health Care Ag filed Critical Novo Nordisk Health Care Ag
Publication of WO2005115442A1 publication Critical patent/WO2005115442A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the present invention relates to a method for treating post surgical bleeding episodes by the post surgical administration of factor XIII to a patient in need thereof.
  • Post surgical bleedings can be a serious complication after various surgical procedures. In the case of cardiac surgery 3-5 % of the patients need reoperation due to uncontrollable post surgical bleeding. It is possible to reduce blood loss by administrating aprotinin or ⁇ -amino capronic acid; however these agents are only effective if administered prior to surgery. Due to the cost of aprotinin, this drug is in many hospitals only administered to high risk patients.
  • Factor XIII the fibrin stabilising factor
  • FXIII is a transglutaminase that binds to and cross-links fibrin monomers in the haemostatic plug thereby providing a fibrin structure with increased mechanical strength and resistance against f ibrinolysis (see Ariens et al, Blood 100(3), 743-754 (2002)).
  • Factor XIII is also known as "fibrinoligase” and "fibrin stabilizing factor”. When activated, factor Xllla is able to form intermolecular gamma-glutamyl- ⁇ -lysine cross-links between side chains of fibrin molecules and other substrates.
  • Factor XIII is found in plasma and in platelets.
  • the enzyme exists in plasma as a tetrameric zymogen consisting of two A-subunits (also referred to as “a”) and two B subunits (also referred to as “b") (this tetrameric zymogen is designated A 2 B 2 or a 2 b 2 ) and in platelets as a zymogen consisting of two A-subunits (this dimeric zymogen is designated A 2 - or a 2 -dimer). Both zymogens are activated by thro bin and Ca 2+ . Ca 2+ is released from the platelets upon aggregation at the site of injury. Thrombin cleaves off the N-terminal 37 amino acid residues of the A subunit of factor XIII.
  • the B-subunits are dissociated from the activated A-subunits.
  • Ca 2+ binds equally well to the zymogen and to the thrombin modified molecule.
  • the active centre cysteine on the A-subunit is exposed and the fully activated enzyme is formed.
  • Subjects with severe thrombocytopenia have been found to have low plasma levels of factor XIII.
  • WO 93/12813 (ZymoGenetics) concerns the use of factor XIII for reducing perioperative blood loss in a subject undergoing surgery.
  • the factor XIII is administered to the subject prior to or during surgery. Not all patients undergoing surgery experiences post surgical bleedings. Therefore it will be an advantage to have haemostatic agents effective in controlling post surgical bleedings when administrated post surgery in case excessive bleeding is observed.
  • the present invention concerns methods of reducing post surgical bleeding and methods of reducing post surgical drainage in a patient after surgery, wherein the method comprises post surgical administration to said patient of an effective amount of factor XIII.
  • Figure 1 shows the overall clot formation after surgery using factor XIII alone and factor XIII in combination with factor Vila.
  • Figure 2 shows the post surgical blood loss from six pigs undergoing cardiac surgery with three hours cardio pulmonary bypass. Data from individual animals as well as median value (line) are shown.
  • the present invention concerns the post surgical administration of factor XIII alone or in combination with other haemostatic agents e.g. factor Vila or factor XI for the treatment of post surgical bleeding episodes.
  • haemostatic agent(s) are effective when administrated post surgically and therefore only need to be administrated to the patients showing uncontrollable bleedings after surgery.
  • the present invention provides improved methods for reducing post surgical blood loss in patients having undergone surgery, in particular, in patients coming out of major thoracic or abdominal surgery or other surgeries having the potential for loss of large volumes of blood. These methods and compositions reduce or eliminate the need for whole donor blood or blood products, thereby reducing the risk of infection and other adverse side effects, as well as the cost of surgery.
  • an effective amount of factor XIII is combined with a biologically compatible vehicle and administered to a patient.
  • the present invention provides a method of reducing post surgical blood loss in a patient after surgery, wherein the method comprises post surgical administration to said patient of an effective amount of factor XIII.
  • the present invention provides a method of reducing post surgical drainage in a patient after surgery, wherein the method comprises post surgical administration to said patient of an effective amount of factor XIII.
  • factor XIII means any protein with transglutaminase activity similar to plasma derived coagulation factor XIII, i.e. plasma derived factor XIII, platelet derived factor XIII, recombinant factor XIII A 2 B 2 , A 2 subunits, or A subunit, as well as genetically modified variants or chemically modified derivatives hereof, wherein these genetically modified variants or chemically modified derivatives have retained at least part of the activity of factor XIII.
  • plasma derived coagulation factor XIII i.e. plasma derived factor XIII, platelet derived factor XIII, recombinant factor XIII A 2 B 2 , A 2 subunits, or A subunit, as well as genetically modified variants or chemically modified derivatives hereof, wherein these genetically modified variants or chemically modified derivatives have retained at least part of the activity of factor XIII.
  • factor XIII variants include: factor XIII in which one or more N-linked or O-linked glycosylation consensus sites have been modified, and cysteine variants in which one or more cysteine residues are eliminated or relocated, including, but not limited to, alterations that change the disulfide bonding pattern of the monomer or dimer.
  • the factor XIII variant is selected among factor XIII variants, which are amino acid sequence variants having no more than 20 amino acids replaced, deleted or inserted compared to wild-type factor XIII (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Patent No.
  • the factor XIII is selected among factor XIII variants, which have no more than 15 amino acids replaced, deleted or inserted; in one embodiment, the factor XIII is selected among factor XIII variants, which have no more than 10 amino acids replaced, deleted or inserted; in one embodiment, the factor XIII is selected among factor XIII variants, which have no more than 8 amino acids replaced, deleted or inserted; in one embodiment, the factor XIII is selected among factor XIII variants, which have no more than 6 amino acids replaced, deleted or inserted; in one embodiment, the factor XIII is selected among factor XIII variants, which have no more than 5 amino acids replaced, deleted or inserted; in one embodiment, the factor XIII is selected among factor XIII variants, which have no more than 3 amino acids replaced, deleted or inserted compared to wild-type factor XIII.
  • factor XIII derivatives include: wild-type factor XIII or factor XIII variants that have been modified by phosphorylation, sulfation, PEGylation, or by the action of one or more glycosyltransferases and/or glycosidases, whether in vivo or in vitro. Also encompassed by the invention are chimeric or fusion polypeptides between all or part of the factor XIII sequence and other heterologous peptide sequences.
  • a binding site for LDL Receptor-associated protein (such as, e.g., a peptide comprising residues Phe342-Asn346 of Factor IXa, which has been shown to contribute to the interaction with LRP, Rohlena et al., J. Biol. Chem. 278, 9394 (2003)) is attached to the sequence of factor XIII to modify its pharmacokinetic properties.
  • the factor XIII protein used is a factor XIII protein syngeneic with the patient in order to reduce the potential risk of inducing an immune response. Preparation and characterization of non-human factor XIII has been disclosed by Nakamura et al. (J. Biochem.
  • an "effective amount" of a factor XIII, and other compounds for use in the present invention is defined as the amount of the compound, which is sufficient to reduce bleeding or blood loss after surgery. It is understood that the effective amount of these compounds may be higher, when the factors are administered without the other compounds being administered than when these compounds are administered to the same patients, whether or not the administration takes place at the same time. An effective amount may for instance be an amount sufficient to reduce blood loss after surgery by at least 15%. The amount of factor XIII administered will be sufficient to provide a supranormal plasma level of factor XIII.
  • factor XIII will generally be in the range of about 0.1 to 1.0 mg per kg of patient weight (i.e. in this example a dose of about 10 mg to about 70 mg for a 70 kg patient). Doses may also be in the range of about 0.15 mg to 0.4 mg per kg of patient weight, for instance about 0.25 mg per kg of patient weight.
  • the actual amount of factor XIII administered will depend in part on such factors as the nature of the surgery and overall patient condition, including pre-existing factor XIII levels.
  • Factor XIII for use within the present invention may be prepared from plasma according to known methods, such as those disclosed by Cooke and Holbrook (Biochem. J. 141, 79-84, 1974) and Curtis and Lorand (Methods Enzymol.
  • factor XIII may be prepared from placenta as disclosed in U.S. Patents 3,904,751 ; 3,931 ,399; 4,597,899 and 4,285,933, incorporated herein by reference.
  • Factor XIII for use within the present invention may also be recombinant factor XIII so as to avoid the use of blood- or tissue-derived products that carry a risk of disease transmission. Methods for preparing recombinant factor XIII are known in the art.
  • the factor XIII is prepared cytoplasmically in the yeast Pichica pastoris as described in Park et al., Biotechnology Letters 24(2), 97-101 (2002). In one embodiment, the factor XIII is prepared in Escherichia coli as described in Lai
  • the factor XIII A 2 dimer is prepared cytoplasmically in the yeast Saccharomyces cerevisiae as disclosed in United States Patent Application Publication No. US 5,612,456 and PCT application WO93/03147, incorporated herein by reference in their entirety.
  • the cells are harvested and lysed, and a cleared lysate is prepared.
  • the lysate is fractionated by anion exchange chromatography at neutral to slightly alkaline pH using a column of derivatized agarose, such as DEAE Fast-FlowSepharoseTM (Pharmacia) or the like.
  • a "post surgical" time period encompasses the time period starting immediately after surgery and ending about 48 hours later. In one embodiment, the "post surgical" time period encompasses the time period starting immediately after surgery and ending about 36 hours later. In one embodiment, the post surgical time period encompasses the time period starting immediately after surgery and ending about 24 hours later. In one embodiment, the post surgical time period encompasses the time period starting immediately after surgery and ending about 18 hours later.
  • a post surgical bleeding episode is a bleeding episode which starts within the post surgical time period.
  • the post surgical bleeding episode - whether treated according to the present invention or not - may end after the expiry of the post surgical time period.
  • a post surgical bleeding episode may for instaiace encompass post surgical drainage.
  • a post surgical administration is an administration regime, which is initiated within the post surgical time period.
  • a post surgical administration regime may comprise a single administration, which is then performed within the post surgical time period. However, a post surgical administration regime may also comprise two or more administrations of which only the first one needs to be performed within the post surgical time period.
  • The. purpose of a post surgical administration regime according to the present invention is to treat one or more post surgical bleeding episodes. In one embodiment, the patient does not suffer from congenital factor XIII deficiency.
  • the factor XIII is a recombinant factor XIII. In one embodiment, the factor XIII is a factor XIII A 2 dimer. In one embodiment, the factor XIII is a factor XIII A monomer. In one embodiment, the factor XIII is administered at a dose of from about 0.1 to about 1.0 mg per kg of patient weight. In one embodiment, the factor XIII is administered at a dose of from about 0.15 to about 0.4 mg per kg of patient weight. In one embodiment, the factor XIII is administered at a dose of about 0.25 mg per kg of patient weight. In one embodiment, no pre-operative administration of factor XIII takes place. In one embodiment, no pre-operative administration of factor XIII takes place within 1 hour prior to surgery. In one embodiment, no pre-operative administration of factor XIII takes place within 2 hours prior to surgery. In one embodiment, no pre-operative administration of factor XIII takes place within 4 hours prior to surgery. In one embodiment, no pre-operative administration of factor XIII takes place within
  • no pre-operative administration of factor XIII takes place within 12 hours prior to surgery. In one embodiment, no pre-operative administration of factor XIII takes place within 24 hours prior to surgery. In one embodiment, no pre-operative administration of factor XIII takes place within 48 hours prior to surgery. In one embodiment, no pre-operative administration of factor XIII takes place within seven days prior to surgery. In one embodiment, the patient is treated with an effective amount of factor Vila prior to, during or after surgery.
  • factor VII includes zymogen factor VII (single-chain factor VII), activated factor VII (FVIIa) as well as genetically modified variants or chemically modified derivatives hereof, wherein these genetically modified variants or chemically modified derivatives have retained at least part of the activity of factor VII or Vila.
  • Non-limiting examples of factor VII variants having substantially the same or better biological activity compared to wild-type factor Vila include, but are not limited to, those described in Danish Patent Applications Nos. PA 2000 00734, PA 2000 01360, PA 2000 01361 , and PA 2001 00477.
  • the factor Vila variant is selected among factor Vila variants, which are amino acid sequence variants having no more than 20 amino acids replaced, deleted or inserted compared to wild-type factor Vila (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Patent No.
  • the factor Vila is selected among factor Vila variants, which have no more than 15 amino acids replaced, deleted or inserted; in one embodiment, the factor Vila is selected among factor Vila variants, which have no more than 10 amino acids replaced, deleted or inserted; in one embodiment, the factor Vila is selected among factor Vila variants, which have no more than 8 amino acids replaced, deleted or inserted; in one embodiment, the factor Vila is selected among factor Vila variants, which have no more than 6 amino acids replaced, deleted or inserted; in one embodiment, the factor Vila is selected among factor Vila variants, which have no more than 5 amino acids replaced, deleted or inserted; in one embodiment, the factor Vila is selected among factor Vila variants, which have no more than 3 amino acids replaced, deleted or inserted compared to wild-type factor Vila.
  • the factor Vila variants are selected from the list of [L305V]-FVIIa, [L305V/M306D/D309S]-FVIIa, [L305l]-FVIIa, [L305T]-FVIIa, [F374P]-FVIIa, [V158T/M298Q]- FVIIa, [V158D/E296V/M298Q]-FVIIa and [K337A]-FVIIa.
  • factor VII derivatives include: wild-type factor VII or factor
  • LRP LDL Receptor-associated protein
  • Factor VII polypeptides for use in the present invention include, without limitation, polypeptides exhibiting substantially the same or improved biological activity relative to wild-type human factor VII, as well as polypeptides in which the factor VII biological activity has been substantially modified or reduced relative to the activity of wild-type human factor VII.
  • the patient is treated with an effective amount of factor VIII prior to, during or after surgery.
  • factor VIII includes factor VIII polypeptides derived from blood or plasma or from platelets or those produced by recombinant means in any suitable host organism or cell.
  • factor VIII polypeptides in their uncleaved (zymogen) form, factor VII polypeptides that have been proteolytically processed to yield their respective bioactive forms (designated factor Villa) as well as genetically modified variants or chemically modified derivatives hereof, wherein these genetically modified variants or chemically modified derivatives have retained at least part of the activity of factor VIII.
  • factor VIII variants include: factor VIII in which one or more N-linked or O-linked glycosylation consensus sites have been modified, and cysteine variants in which one or more cysteine residues are eliminated or relocated, including, but not limited to, alterations that change the disulfide bonding pattern of the monomer or dimer.
  • the factor VIII variant is selected among factor VIII variants, which are amino acid sequence variants having no more than 20 amino acids replaced, deleted or inserted compared to wild-type factor VIII (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Patent No.
  • the factor VIII is selected among factor VIII variants, which have no more than 15 amino acids replaced, deleted or inserted; in one embodiment, the factor VIII is selected among factor VIII variants, which have no more than 10 amino acids replaced, deleted or inserted; in one embodiment, the factor VIII is selected among factor VIII variants, which have no more than 8 amino acids replaced, deleted or inserted; in one embodiment, the factor VIII is selected among factor VIII variants, which have no more than 6 amino acids replaced, deleted or inserted; in one embodiment, the factor VIII is selected among factor VIII variants, which have no more than 5 amino acids replaced, deleted or inserted; in one embodiment, the factor VIII is selected among factor VIII variants, which have no more than 3 amino acids replaced, deleted or inserted compared to wild-type factor VIII.
  • factor VIII derivatives include: wild-type factor VIII or factor
  • LRP LDL Receptor-associated protein
  • Factor VIII polypeptides for use in the present invention include, without limitation, polypeptides exhibiting substantially the same or improved biological activity relative to wild-type human factor VIII, as well as polypeptides in which the factor VIII biological activity has been substantially modified or reduced relative to the activity of wild-type human factor VIII.
  • the patient is treated with an effective amount of factor XI prior to, during or after surgery.
  • factor XI includes factor XI polypeptides derived from blood or plasma or from platelets or those produced by recombinant means in any suitable host organism or cell.
  • factor XI polypeptides in their uncleaved (zymogen) form factor XI polypeptides, that have been proteolytically processed to yield their respective bioactive forms (designated factor Xla)as well as genetically modified variants or chemically modified derivatives hereof, wherein these genetically modified variants or chemically modified derivatives have retained at least part of the activity of factor XI.
  • factor XI variants include: factor XI in which one or more N- linked or O-linked glycosylation consensus sites have been modified, single-chain factor XI (i.e., factor XI in which the monomer polypeptides are not subject to intrachain proteolytic cleavage as in the wild-type), and cysteine variants in which one or more cysteine residues are eliminated or relocated, including, but not limited to, alterations that change the disulfide bonding pattern of the monomer or dimer.
  • Cys11 which is not believed to participate in inter- or intramolecular disulfide bonding is eliminated or substituted.
  • the factor XI variant is selected among factor XI variants, which are amino acid sequence variants having no more than 20 amino acids replaced, deleted or inserted compared to wild-type factor XI (i.e., a polypeptide having the amino acid sequence disclosed in U.S. Patent No.
  • the factor XI is selected among factor XI variants, which have no more than 15 amino acids replaced, deleted or inserted; in one embodiment, the factor XI is selected among factor XI variants, which have no more than 10 amino acids replaced, deleted or inserted; in one embodiment, the factor XI is selected among factor XI variants, which have no more than 8 amino acids replaced, deleted or inserted; in one embodiment, the factor XI is selected among factor XI variants, which have no more than 6 amino acids replaced, deleted or inserted; in one embodiment, the factor XI is selected among factor XI variants, which have no more than 5 amino acids replaced, deleted or inserted; in one embodiment, the factor XI is selected among factor XI variants, which have no more than 3 amino acids replaced, deleted or inserted compared to wild-type factor XI.
  • Non-limiting examples of factor XI derivatives include: wild-type factor XI or factor XI variants that have been modified by phosphorylation, sulfation, PEGylation, or by the action of one or more glycosyltransferases and/or glycosidases, whether in vivo or in vitro (see, e.g., Ekdahl et al., Thromb. Haemost. 82, 1283-8 (1999)). Also encompassed by the invention are chimeric or fusion polypeptides between all or part of the factor XI sequence and other heterologous peptide sequences.
  • one or more of the four Apple domains may be substituted by similar apple domains from other polypeptides (see, e.g., Gailani et al., Blood 94, 621a (1999)) or one or more of the Apple domains may be deleted in its entirety.
  • a binding site for LDL Receptor-associated protein (LRP) (such as, e.g., a peptide comprising residues Phe342- Asn346 of Factor IXa, which has been shown to contribute to the interaction with LRP, Rohlena et al., J. Biol. Chem. 278, 9394 (2003)) is attached to the sequence of factor XI to modify its pharmacokinetic properties.
  • LRP LDL Receptor-associated protein
  • factor XI Due to the dimeric nature of factor XI in its active form (and the asymmetric function of the two monomers in, e.g., platelet binding and FIX activation), factor XI also encompasses factor XI heterodimers, i.e., combinations of two non- identical factor XI (or factor Xl-related) monomer polypeptides. The only requirement is that the heterodimer exhibit one or more beneficial aspects of factor XI bioactivity.
  • Factor XI polypeptides for use in the present invention include, without limitation, polypeptides exhibiting substantially the same or improved biological activity relative to wild-type human factor XI, as well as polypeptides in which the factor XI biological activity has been substantially modified or reduced relative to the activity of wild-type human factor XI.
  • the patient is treated with an effective amount of a TFPI inhibitor prior to, during or after surgery.
  • TFPI inhibitor means compounds inhibiting the anti-coagulative activity of TFPI (tissue factor pathway inhibitor).
  • the term includes compounds such as those disclosed in European Patent No. 558 529, WO 96/28153 and US 5,622,988.
  • the present invention also provides the use of factor XIII for the preparation of a pharmaceutical composition for reducing post surgical blood loss in a patient after surgery.
  • the pharmaceutical composition is for administration after surgery.
  • the patient does not suffer from congenital factor XIII deficiency.
  • the factor XIII is recombinant factor XIII.
  • the factor XIII is a factor XIII A 2 dimer.
  • the factor XIII is a factor XIII A monomer.
  • the pharmaceutical composition is to be administered at a dose of from about 0.1 to about 1.0 mg per kg of patient weight.
  • the pharmaceutical composition is to be administered at a dose of from about 0.15 to about 0.4 mg per kg of patient weight. In one embodiment, the pharmaceutical composition is to be administered at a dose of about 0.25 mg per kg of patient weight.
  • the patient is treated with an effective amount of factor Vila prior to, during or after surgery. In one embodiment, the patient is treated with an effective amount of factor VIII prior to, during or after surgery. In one embodiment, the patient is treated with an effective amount of factor XI prior to, during or after surgery. In one embodiment, the patient is treated with an effective amount of a TFPI inhibitor prior to, during or after surgery.
  • the present invention provides the use of factor XIII for the preparation of a pharmaceutical composition for the stated purposes, wherein the pharmaceutical composition also comprises factor Vila. In one embodiment, the present invention provides the use of factor XIII for the preparation of a pharmaceutical composition for the stated purposes, wherein the pharmaceutical composition also comprises factor VIII. In one embodiment, the present invention provides the use of factor XIII for the preparation of a pharmaceutical composition for the stated purposes, wherein the pharmaceutical composition also comprises factor XI. In one embodiment, the present invention provides the use of factor XIII for the preparation of a pharmaceutical composition for the stated purposes, wherein the pharmaceutical composition also comprises factor Vila and factor VIII.
  • the present invention provides the use of factor XIII for the preparation of a pharmaceutical composition for the stated purposes, wherein the pharmaceutical composition also comprises factor Vila and factor XI. In one embodiment, the present invention provides the use of factor XIII for the preparation of a pharmaceutical composition for the stated purposes, wherein the pharmaceutical composition also comprises factor Vila, factor VIII and factor XI. In one embodiment, the present invention provides the use of factor XIII for the preparation of a pharmaceutical composition for the stated purposes, wherein the pharmaceutical composition also comprises factor VIII and factor XI.
  • the present invention encompasses pharmaceutical compositions comprising a preparation of factor XIII for post surgical administration. In one embodiment, the pharmaceutical compositions are administered parenterally, i.e., intravenously, subcutaneously, or intramuscularly.
  • compositions according to the invention comprise a factor XIII, preferably dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier or diluent.
  • pharmaceutical compositions suitable for use according to the present invention are made by mixing a preparation comprising factor XIII, preferably in purified form, with suitable adjuvants and a suitable carrier or diluent.
  • aqueous carriers such as water, buffered water, saline (for instance 0.4%), glycine (for instance 0.3%), sugars, detergents, salts, buffers, glycerols, conservating agents, protease inhibitors, glycols, and the like.
  • the pharmaceutical compostions of the present invention can also be formulated using non-aqueous carriers, such as, e.g., in the form of a gel or as liposome preparations for delivery or targeting to the sites of injury. Liposome preparations are generally described in, e.g., U.S. Patents Nos. 4,837,028, 4,501 ,728, and 4,975,282.
  • compositions may be sterilised by conventional, well-known sterilisation techniques.
  • the resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilised, the lyophilised preparation being combined with a sterile aqueous solution prior to administration.
  • the compositions may contain pharmaceutically acceptable auxiliary substances or adjuvants, including, without limitation, pH adjusting and buffering agents and/or tonicity adjusting agents, such as, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
  • the compositions may further include one or more diluents, emulsifiers, preservatives, buffers, excipients, etc.
  • compositions according to the present invention may be provided in such forms as liquids, powders, emulsions, controlled release, etc.
  • One skilled in this art may formulate the compositions according to the present invention in an appropriate manner, and in accordance with accepted practices, such as those disclosed in Remington's Pharmaceutical Sciences, Gennaro, ed., Mack Publishing Co., Easton, PA, 1990.
  • Local delivery of the preparations of the present invention may be carried out, e.g., by means of a spray, perfusion, double balloon catheters, stent, incorporated into vascular grafts or stents, hydrogels used to coat balloon catheters, incorporation into gauze or other bandage materials, or other well established methods.
  • the invention provides a pharmaceutical product comprising (a) a composition comprising factor XIII alone or combined with one or more other haemostatic agents, such as for instance factor Vila, factor VIII or factor XI, (b) a pharmaceutically acceptable carrier, vehicle, excipient, diluent, preservative, stabilizer, binder, flavouring agent, an antioxidant, a colorant, adjuvant, disintegrating agent, solvent, a solubilizer, a suspending agent, a isotonizing/isotonic agent, a buffer, a soothing agent, or combination of any thereof as exemplified above, and, optionally, (c) a notice associated with said container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by said agency of said pharmaceutical product for human or veterinary administration to reduce post surgical blood loss.
  • a pharmaceutically acceptable carrier vehicle, excipient, diluent, preservative, stabilizer, binder, flavouring agent, an antioxidant,
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a unit dosage form; and b) container means for containing said dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a factor Vila and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) container means for containing said dosage form.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a TFPI inhibitor and, optionally, a i, pharmaceutically acceptable carrier in a unit dosage form; and • b) container means for containing said dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; c) an effective amount of a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a third unit dosage form; and d) container means for containing said first, second and third dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor Vila and a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a factor Vila and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) an effective amount of a factor VIII and, optionally, a pharmaceutically acceptable carrier in a third dosage form; and d) an effective amount of a TFPI-inhibitor and, optionally, a pharmaceutically acceptable carrier in a fourth dosage form; and e) container means for containing said first, second, third and fourth dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a factor Vila and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor VIII and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; c) an effective amount of a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a third unit dosage form; and d) container means for containing said first, second and third dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) an effective amount of a factor VIII and, optionally, a pharmaceutically acceptable carrier in a third unit dosage form; and d) container means for containing said first, second and third dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a factor VIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) an effective amount of a TFPI-inhibitor and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and d) container means for containing said first, second and third dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a factor Vila and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor VIII and a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a TFPI-inhibitor and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor VIII and a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor XIII and a factor VIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a TFPI-inhibitor and a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) container means for containing said first and second dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor Vila and a factor VIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) an effective amount of a TFPI inhibitor and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and d) container means for containing said first, second and third dosage forms.
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a factor Vila and a TFPI-inhibitor and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form;
  • the present invention provides a kit containing a treatment for post surgical bleeding episodes, said kit comprising a) an effective amount of a TFPI-inhibitor and a factor VIII and, optionally, a pharmaceutically acceptable carrier in a first unit dosage form; b) an effective amount of a factor XIII and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and c) an effective amount of a factor Vila and, optionally, a pharmaceutically acceptable carrier in a second unit dosage form; and d) container means for containing said first, second and third dosage forms.
  • Recombinant factor XIII A or A 2 subunits has been produced and tested for effect on mechanical strength of clots formed ex vivo using blood from patients undergoing cardiac surgery as will be shown in the following non-limiting examples. None of the patients suffered from congenital factor XIII deficiency. Factor XIII alone or in combination with factor Vila improves the mechanical strength of the clots formed.
  • Example 1 Recombinant factor XIII A or A 2 subunits has been produced and tested for effect on mechanical strength and resistance against fibrinolysis of clots formed ex vivo using blood from patients undergoing cardiac surgery.
  • Factor XIII alone or in combination with factor Vila improves the mechanical strength of the clots formed.
  • Blood was obtained before and after surgery from 3 patients undergoing cardiac surgery with cardiopulmonary bypass.
  • the effect of factor XIII on clot formation and stability was evaluated using rotational thromboelastography (roTEG), using the method of Vig et al. Blood Coag Fibrinol. 12, 555 (2001 ).
  • coagulation in whole citrated blood was initiated by adding lipidated tissue factor (innovin (Dade Behring) at a final dilution of 1 :50,000) and CaCI 2 (final concentration 15 nM), in the presence or absence of factor XIII (120 nM A subunit) or factor XIII (120nM A subunit) in combination with factor Vila (25nM).
  • Fibrinolysis was initiated by addition of 4 nM tPA (American Diagnostica). Measurements were made using a ROTEG-04 Whole Blood Haemostasis System Rotation Thrombelastography apparatus (Pentapharm GmBH).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur l'administration post-opératoire du facteur XIII seul ou en combinaison avec d'autres agents hémostatiques tels que le facteur VIIa ou le facteur XI dans le traitement de phases de saignements post-opératoires. Ces agents hémostatiques sont efficaces lorsqu'il sont administrés après une intervention chirurgicale et, par conséquent, nécessitent seulement d'être administrés à des patients présentant des saignements irrépressibles après une intervention chirurgicale.
PCT/EP2005/052324 2004-05-25 2005-05-20 Utilisation du facteur xiii de coagulation dans le traitement de saignements post-operatoires WO2005115442A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400816 2004-05-25
DKPA200400816 2004-05-25

Publications (1)

Publication Number Publication Date
WO2005115442A1 true WO2005115442A1 (fr) 2005-12-08

Family

ID=34968863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/052324 WO2005115442A1 (fr) 2004-05-25 2005-05-20 Utilisation du facteur xiii de coagulation dans le traitement de saignements post-operatoires

Country Status (1)

Country Link
WO (1) WO2005115442A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012010626A1 (fr) * 2010-07-22 2012-01-26 Csl Behring Gmbh Cascade de coagulation d'une sérine protéase ancestrale exerçant une nouvelle fonction dans la défense immunitaire précoce
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
US8466108B2 (en) 2008-12-19 2013-06-18 Baxter International Inc. TFPI inhibitors and methods of use
US8962563B2 (en) 2009-12-21 2015-02-24 Baxter International, Inc. TFPI inhibitors and methods of use
CN105985428A (zh) * 2015-02-10 2016-10-05 许健 人重组凝血因子ⅹⅲ的促凝血功能

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012813A1 (fr) * 1991-12-31 1993-07-08 Zymogenetics, Inc. Procedes et compositions pour reduire la perte de sang
WO1994011022A1 (fr) * 1992-11-12 1994-05-26 Zymogenetics, Inc. Procede et utilisation du facteur xiii en application locale pour empecher une hemorragie
WO2001085198A1 (fr) * 2000-05-10 2001-11-15 Novo Nordisk A/S Composition pharmaceutique comprenant un facteur viia et un facteur xiii
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012813A1 (fr) * 1991-12-31 1993-07-08 Zymogenetics, Inc. Procedes et compositions pour reduire la perte de sang
WO1994011022A1 (fr) * 1992-11-12 1994-05-26 Zymogenetics, Inc. Procede et utilisation du facteur xiii en application locale pour empecher une hemorragie
WO2001085198A1 (fr) * 2000-05-10 2001-11-15 Novo Nordisk A/S Composition pharmaceutique comprenant un facteur viia et un facteur xiii
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GERLACH R ET AL: "Increased risk for postoperative hemorrhage after intracranial surgery in patients with decreased factor XIII activity: Implications of a prospective study", STROKE 2002 UNITED STATES, vol. 33, no. 6, 2002, pages 1618 - 1623, XP002342933, ISSN: 0039-2499 *
GOEDJE O ET AL: "THE EFFECT OF FACTOR XIII ON BLEEDING IN CORONARY SURGERY", THORACIC AND CARDIOVASCULAR SURGEON, THIEME MED. PUB., NEW YORK, NY,, US, vol. 46, no. 5, October 1998 (1998-10-01), pages 263 - 267, XP009018964, ISSN: 0171-6425 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9873720B2 (en) 2008-12-19 2018-01-23 Baxalta GmbH TFPI inhibitors and methods of use
US9777051B2 (en) 2008-12-19 2017-10-03 Baxalta GmbH TFPI inhibitors and methods of use
US11001613B2 (en) 2008-12-19 2021-05-11 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
US8466108B2 (en) 2008-12-19 2013-06-18 Baxter International Inc. TFPI inhibitors and methods of use
US8962563B2 (en) 2009-12-21 2015-02-24 Baxter International, Inc. TFPI inhibitors and methods of use
US9018167B2 (en) 2010-03-19 2015-04-28 Baxter International Inc. TFPI inhibitors and methods of use
US10201586B2 (en) 2010-03-19 2019-02-12 Baxalta GmbH TFPI inhibitors and methods of use
US9556230B2 (en) 2010-03-19 2017-01-31 Baxalta GmbH TFPI inhibitors and methods of use
US8450275B2 (en) 2010-03-19 2013-05-28 Baxter International Inc. TFPI inhibitors and methods of use
US11793855B2 (en) 2010-03-19 2023-10-24 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
CN103079588A (zh) * 2010-07-22 2013-05-01 德国杰特贝林生物制品有限公司 祖先丝氨酸蛋白酶凝血级联在早期免疫防御中发挥新功能
WO2012010626A1 (fr) * 2010-07-22 2012-01-26 Csl Behring Gmbh Cascade de coagulation d'une sérine protéase ancestrale exerçant une nouvelle fonction dans la défense immunitaire précoce
US10800816B2 (en) 2012-03-21 2020-10-13 Baxalta GmbH TFPI inhibitors and methods of use
CN105985428A (zh) * 2015-02-10 2016-10-05 许健 人重组凝血因子ⅹⅲ的促凝血功能

Similar Documents

Publication Publication Date Title
AU2003234743B2 (en) Storage-stable, liquid fibrinogen formulation
EP2125004B1 (fr) Utilisation thérapeutique synergique de concentrés de complexe prothrombinique avec des concentrés de fviii
JP6425674B2 (ja) 凍結乾燥した組換え型ｖｗｆ製剤
JP6250282B2 (ja) 出血性障害の治療および予防的治療における非静脈内投与のためのアルブミン融合凝固因子
US6825323B2 (en) Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
JP5801789B2 (ja) トロンビンを含まない生物学的接着剤及びその医薬としての使用
JP2001515460A (ja) 血漿タンパク質液体製剤の製造法と使用法
CZ20023667A3 (cs) Farmaceutický prostředek obsahující VIIA a XIII faktory
JP5253501B2 (ja) 安定化トロンビン組成物
US20090017007A1 (en) Liquid factor vii composition
JP6514893B2 (ja) 止血を調節するための組成物および方法
US10004787B2 (en) Fibrinogen preparations enriched in fibrinogen with an extended alpha chain
WO2005115442A1 (fr) Utilisation du facteur xiii de coagulation dans le traitement de saignements post-operatoires
EP0754463A2 (fr) Préparation liquide stabilisée de facteur de coagulation sanguin XIII
CA2722230A1 (fr) Composition de transglutaminase seche
JP5236952B2 (ja) 改善された特性を有するｆｘｉｉｉバリアント
CN111565741A (zh) 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者
JP2020526525A (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
RU2272648C2 (ru) Фармацевтическая композиция, содержащая фактор viia и фактор xiii
KR20020092469A (ko) 인자 ＶＩＩａ 및 인자 ＸＩＩＩ를 포함하는 제약학적조성물
MXPA02011042A (en) tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII
CA2460023A1 (fr) Methode de traitement d'hemorragie induite par la coumarine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase